片仔癀：PZH2108片Ⅱa期临床试验完成首例受试者入组

Core Viewpoint - The company, Pianzihuang (600436.SH), has announced that its innovative chemical drug PZH2108 has completed the enrollment of the first subject in the Phase IIa clinical trial, aimed at treating cancer pain [1] Company Summary - The cumulative research and development investment for PZH2108 has reached approximately 61 million yuan [1] - As of the announcement date, no other companies have obtained production licenses for this product, and there are no approved drugs targeting the same indication as PZH2108 [1]